Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.

Paul M Kaye; Israel Cruz; Albert Picado; Katrien Van Bocxlaer; Simon L Croft ORCID logo; (2020) Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs. Springer Seminars in Immunopathology, 42 (3). pp. 247-264. ISSN 1863-2297 DOI: 10.1007/s00281-020-00788-y
Copy

Leishmaniasis is a disease complex caused by 20 species of protozoan parasites belonging to the genus Leishmania. In humans, it has two main clinical forms, visceral leishmaniasis (VL) and cutaneous or tegumentary leishmaniasis (CL), as well as several other cutaneous manifestations in a minority of cases. In the mammalian host Leishmania parasites infect different populations of macrophages where they multiply and survive in the phagolysosomal compartment. The progression of both VL and CL depends on the maintenance of a parasite-specific immunosuppressive state based around this host macrophage infection. The complexity and variation of immune responses and immunopathology in humans and the different host interactions of the different Leishmania species has an impact upon the effectiveness of vaccines, diagnostics and drugs.


picture_as_pdf
Kaye-etal-2020_Leishmaniasis_immunopathology_impact_on_design.pdf
subject
Accepted Version
Available under Creative Commons: NC-ND 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads